{"id":59040,"date":"2023-06-15T14:39:49","date_gmt":"2023-06-15T09:09:49","guid":{"rendered":"http:\/\/finservwealth.com\/solara-active-pharma-spurts-9-on-heavy-volumes\/"},"modified":"2023-06-15T14:39:49","modified_gmt":"2023-06-15T09:09:49","slug":"solara-active-pharma-spurts-9-on-heavy-volumes","status":"publish","type":"post","link":"https:\/\/finservwealth.com\/hi\/solara-active-pharma-spurts-9-on-heavy-volumes\/","title":{"rendered":"Solara Active Pharma spurts 9% on heavy volumes"},"content":{"rendered":"<p> The stock saw a sharp upmove of 300 percent between March 2020 and July 2021, touching Rs 1,800 as COVID outbreak led to a spike in demand for its main offerings \u00e2\u20ac\u201d Ibuprofen, Favipiravir and Gabapentin<\/p><div id=\"finse-2599393985\" class=\"finse-content finse-entity-placement\"><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-9118214110898834\" crossorigin=\"anonymous\"><\/script><ins class=\"adsbygoogle\" style=\"display:block;\" data-ad-client=\"ca-pub-9118214110898834\" \ndata-ad-slot=\"\" \ndata-ad-format=\"auto\"><\/ins>\n<script> \n(adsbygoogle = window.adsbygoogle || []).push({}); \n<\/script>\n<\/div>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/solara-active-pharma-spurts-9heavy-volumes_17082761.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0The stock saw a sharp upmove of 300 percent between March 2020 and July 2021, touching Rs 1,800 as COVID outbreak led to a spike in demand for its main offerings \u00e2\u20ac\u201d Ibuprofen, Favipiravir and Gabapentin The stock saw a sharp upmove of 300 percent between March 2020 and July 2021, touching Rs 1,800 as COVID outbreak led to a spike in demand for its main offerings \u00e2\u20ac\u201d Ibuprofen, Favipiravir and Gabapentin\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/solara-active-pharma-spurts-9heavy-volumes_17082761.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p> The stock saw a sharp upmove of 300 percent between March 2020 and July 2021, touching Rs 1,800 as COVID outbreak led to a spike in demand for its main offerings \u00e2\u20ac\u201d Ibuprofen, Favipiravir and Gabapentin<\/p>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/solara-active-pharma-spurts-9heavy-volumes_17082761.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0The stock saw a sharp upmove of 300 percent between March 2020 and July 2021, touching Rs 1,800 as COVID outbreak led to a spike in demand for its main offerings \u00e2\u20ac\u201d Ibuprofen, Favipiravir and Gabapentin The stock saw a sharp upmove of 300 percent between March 2020 and July 2021, touching Rs 1,800 as COVID outbreak led to a spike in demand for its main offerings \u00e2\u20ac\u201d Ibuprofen, Favipiravir and Gabapentin\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/solara-active-pharma-spurts-9heavy-volumes_17082761.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>\n<p><!-- \/wp:html --> The stock saw a sharp upmove of 300 percent between March 2020 and July 2021, touching Rs 1,800 as COVID outbreak led to a spike in demand for its main offerings \u00e2\u20ac\u201d Ibuprofen, Favipiravir and Gabapentin<\/p>","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[70],"tags":[],"class_list":["post-59040","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest-news"],"jetpack_featured_media_url":"https:\/\/www.moneycontrol.com\/news_image_files\/2021\/200x200\/s\/shutterstock_173323913_200.jpg","_links":{"self":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/59040","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/comments?post=59040"}],"version-history":[{"count":0,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/59040\/revisions"}],"wp:attachment":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/media?parent=59040"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/categories?post=59040"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/tags?post=59040"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}